Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[(11)C](R)-PK11195 PET imaging of inflammation in MS/CIS during natalizumab therapy
2007-007394-22Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of natalizumab in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by Imperial College London. Primary endpoints: Cortical 11C-PK11195 binding potential at baseline and Change in grey matter 11C-PK11195 binding potential over one year. Started Apr 2008; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2007-007394-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007394-22.